[Central mechanisms of therapeutic effectiveness of neuromidin in the treatment of peripheral nerve lesions].
The effect of neuromidin on the modulation of peripheral nerve lesions have been studied in 120 patients. Sixty-two patients of the control group received traditional therapy (nonsteroid anti-inflammatory drugs, myorelaxants, vasoactive drugs, proserin, physiotherapy), 58 patients of the main group alongside with traditional therapy received neuromidin instead of proserin (15 mg/d intramuscular for the first 10 days, 20 mg 3 times a day in tablets during the following 20 days). The duration of the study was 30 days. In the 30th day of the treatment, there were the reduction of severity of paresis, pain and anxiety syndrome, the increase of the M-response amplitude and velocity of impulse conduction along the affected nerves (p< or =0.05) in the main group. The results of magnetic diagnostics and assessment of somatosensory evoked potentials revealed the significant decrease of the central motor and sensory conduction time (p< or =0.05). The modulating effect of neuromidin on the neurotransmitter activity (the increase of plasma serotonin concentration in 15th day of the therapy and the decrease of noradrenalin content in the 30th day) was observed. There were no significant side-effects which required the withdrawal of the drug. The stimulating effect of neuromidin on the neuroplasticity both on peripheral and central levels was found.
S A
SA
Zhivolupov
I N
IN
Samartsev
D000328:Adult; D000634:Aminoquinolines / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009416:Nerve Regeneration / Q000187:drug effects*; D059348:Peripheral Nerve Injuries; D010525:Peripheral Nerves / Q000187:drug effects* / Q000502:physiology; D011446:Prospective Studies
D000634:Aminoquinolines; D002800:Cholinesterase Inhibitors; C049860:amiridine